Sugi Predict

Sugi Predict / Compounds / SCHEMBL2852071

SCHEMBL2852071

SCHEMBL2852071

Cc1ccc(OCc2ccccc2)cc1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 9/20 0.58
▸ RAB9A P51151 3/20 0.58
▸ MAOA P21397 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ GAA P10253 1/20 0.58
▸ MAPT P10636 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ ALOX5 P09917 1/20 0.56
▸ NPC1 O15118 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ PTGS1 P23219 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ PTGS2 P35354 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ HIF1A Q16665 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1894067 0.86 MAOB (0.58) MAOBRAB9AMAOAL3MBTL1GAA
SCHEMBL25947189 0.85 MAOB (0.56) MAOBRAB9AMAPTSMN1; SMN2NPC1
SCHEMBL30040891 0.84 MAOB (0.63) MAOBRAB9AMAOAL3MBTL1GAA
SCHEMBL8335885 0.84 ALOX5 (0.61) MAOBRAB9AMAOAL3MBTL1GAA
SCHEMBL4473165 0.84 MAOB (0.63) MAOBRAB9AMAOAL3MBTL1GAA
SCHEMBL18702749 0.83 RAB9A (0.60) MAOBRAB9AMAOANPC1MEN1
SCHEMBL29502944 0.83 RAB9A (0.60) MAOBRAB9AMAOANPC1MEN1
Hydrochloric Acid SCHEMBL9124176 0.82 MAOB (0.61) MAOBRAB9AMAOAL3MBTL1GAA
SCHEMBL18703243 0.82 MAOA (0.52) RAB9AMAOAMAPTNPC1LMNA
SCHEMBL20526908 0.81 MAOB (0.56) MAOBRAB9AMAOAL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025014200-A1 COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 티움바이오 2025-01-16 — — WO disclosed
US-20220227739-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS INC (US) 2022-07-21 — — US disclosed
WO-2022148821-A1 USP7 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF LOCKI THERAPEUTICS LIMITED (GB) 2022-07-14 — — WO disclosed
CN-108430994-B Compounds, compositions and methods for modulating CFTR 蛋白质平衡治疗股份有限公司 2022-04-12 — — CN disclosed
US-11136313-B2 Compounds, compositions, and methods for modulating CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2021-10-05 — — US disclosed
EP-3359536-B1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS INC (US) 2021-08-04 — — EP disclosed
US-20200385365-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS, INC. 2020-12-10 — — US disclosed
EP-3233828-B1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2020-03-04 — — EP disclosed
US-10550106-B2 Compounds, compositions, and methods for modulating CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2020-02-04 — — US disclosed
US-20180291006-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS, INC. 2018-10-11 — — US disclosed
EP-2119718-B1 MACROCYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2012-04-11 — — EP disclosed
CN-101029022-B Process for producing nitrogen-containing aromatic ring derivative EISAI R&D MAN CO LTD 2011-01-12 — — CN disclosed
US-20100056510-A1 Macrocyclic Compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-04 — — US disclosed
EP-2119718-A1 MACROCYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2009-11-18 — — EP disclosed
CN-100369899-C Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2008-02-20 — — CN disclosed
CN-101029022-A Process for producing nitrogen-containing aromatic ring derivative EISAI R&D MAN CO LTD (JP) 2007-09-05 — — CN disclosed
CN-101024627-A Nitrogen-containing aromatic ring derivatives EISAI R&D MAN CO LTD (JP) 2007-08-29 — — CN disclosed
CN-1308310-C Nitrogen-containing aromatic ring derivatives EISAI CO LTD (JP) 2007-04-04 — — CN disclosed
CN-1894264-A Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors AVENTIS PHARMA SA (FR) 2007-01-10 — — CN disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056510-A1 Macrocyclic Compound HSP90AB1, HSP90B1, HSP90AA1 MAOB 3489/4885RAB9A 2143/4885MAOA 3525/4885
US-11136313-B2 Compounds, compositions, and methods for modulating CFTR CFTR, SCNN1B, SCNN1G MAOB 4409/4885RAB9A 699/4885MAOA 4744/4885
US-20200385365-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G MAOB 4409/4885RAB9A 699/4885MAOA 4744/4885
US-20220227739-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G MAOB 4409/4885RAB9A 699/4885MAOA 4744/4885
US-10550106-B2 Compounds, compositions, and methods for modulating CFTR CFTR, SCNN1B, SCNN1G MAOB 4409/4885RAB9A 699/4885MAOA 4744/4885
US-20180291006-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G MAOB 4409/4885RAB9A 699/4885MAOA 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.